Why BGPT?
logo

Review papers with raw data transparency

Quickly verify claims by accessing the underlying experimental data and figures.







Press Enter ↡ to solve



    Fuel Your Discoveries




     Quick Explanation


    Mechanistic core
    The paper proposes that HDAC11 enzymatically removes lysine myristoylation (K-myr) from SF3B2 at K10, changing SF3B2 pre-mRNA binding and driving a cancer-type-specific shift in AR-v7 vs AR-FL splicing (strongest in HCC cell context).
    Evidence is built from SILAC-MS substrate discovery, Alk14 click-chemistry fatty-acyl readouts, catalytic-mutant controls, and RIP + AR-v7 minigene assays.



     Long Explanation


    Paper Review (Rigorous, skeptical): HDAC11 Regulates RNA Splicing via De-Fatty Acylation of SF3B2

    Paper DOI: 10.64898/2026.02.22.707301 (provided full-text excerpt; analysis strictly grounded in the provided text)
    One-sentence mechanistic model (as claimed)
    HDAC11 de-fatty-acylates SF3B2 at K10, and the resulting de-myristoylated SF3B2 alters SF3B2’s pre-mRNA binding at AR-v7-associated cryptic exon loci, producing a cell-type-specific AR splicing switch in HCC models.
    Claim chain map (from experiments reported)
    Key molecular claim: SF3B2 lipidation site
    The authors report that SF3B2 is fatty-acylated at a single lysine residue, K10, and that a K10R SF3B2 mutant abolishes Alk14-based labeling, supporting K10 as the relevant lipidation site for HDAC11 action.
    PTM site: K10 (claimed as the only mapped lipidated lysine)
    Experimental pillars (what was tested, and what it argues)
    Pillar Experiment/Readout (from text) Reported outcome Logical contribution
    Substrate discovery SILAC-MS with fatty acylation probe logic + cross-reference datasets SF3B2 appears in all referenced datasets among a small shortlist Narrows candidates for HDAC11-dependent lipidation
    Protein–enzyme relationship Co-IP HDAC11–SF3B2; catalytic mutant LOF effect Interaction disrupted by catalytic-dead HDAC11 mutants Supports catalytic substrate dependence (not merely scaffolding)
    De-fatty-acylation assay Alk14 click labeling + immunopurification + Western detection WT HDAC11 removes SF3B2 fatty acylation; catalytic mutant Y304H does not Directly ties HDAC11 catalytic activity to loss of SF3B2 lipidation signal
    Site mapping MS mapping of Alk14-associated lipidation; K10R validation K10 identified as the (single) lysine lipidation site; K10R abolishes signal Specifies the mechanistic PTM locus for downstream functional claims
    Spliceosome functional readout RNA immunopurification (RIP) with WT SF3B2 vs K10R SF3B2 De-myristoylation mimic alters SF3B2 pre-mRNA binding at AR-v7 locus in HCC context Connects PTM to RNA-binding changes at splice regulatory regions
    Splicing outcome & causality tests HDAC11 overexpression/KD; AR exon junction qPCR; AR-v7 minigene rescue logic HDAC11 modulates AR-v7/AR-FL splicing in HCC, requiring catalytic activity; mimic via SF3B2 K10R Implements PTM→splicing causality with mutant/rescue architecture
    Critical assessment (what’s strong vs what remains uncertain)
    Strengths
    • Causal architecture: the work repeatedly uses catalytic-dead HDAC11 logic and a PTM-site mutant (SF3B2 K10R) to connect enzymatic activity β†’ PTM loss β†’ altered binding β†’ splicing phenotypes.
    • Multi-layer mechanism: substrate discovery (MS) is followed by orthogonal biochemical detection (Alk14 click labeling), then site mapping, then RNA-centric functional assays (RIP, minigene, exon junction qPCR).
    Blind spots / known uncertainties (from the provided text)
    • Endogenous PTM detection limitation: the authors explicitly state they cannot directly test endogenous fatty acylation without exogenous Alk14 labeling because of the lack of antibodies for these hydrophobic lipid marks.
    • Alk14 assay perturbation risk: the text reports that Alk14 treatment may destabilize endogenous SF3B2, suggesting the labeling workflow could influence protein stability or the measured partitioning into pulldown fractions.
    • Cell-line specificity remains underspecified: the authors find no AR-v7 splicing phenotype in 22Rv1 under HDAC11 manipulation despite RIP hints, indicating either (i) context-dependent downstream circuitry or (ii) sensitivity limits in the chosen assays/cell states.
    • SUMO mechanism is suggestive, not closed: they propose possible interplay between de-myristoylation and SUMOylation at K10, but do not fully establish biological relevance under endogenous conditions (e.g., no localization/stability changes upon HDAC11 KD).
    • Limited spliceome scope: they focus on AR-v7 as a readout but state other loci are untested; therefore generalizability to genome-wide splicing changes is not demonstrated within the provided text.
    Conceptual interaction network (as supported in the text)
    Nodes represent molecular elements and assays invoked in the proposed axis; edge meanings follow the authors’ claimed directional relationships (modify/bind/splice).
    Reproducibility & methodological clarity (from the provided methods)
    • The methods section includes substantial detail on cell culture, plasmid construction, transfection/stable line selection, and the Alk14 click-chemistry workflow plus IP/SDS-PAGE/WB steps, which improves practical reproducibility.
    • However, key quantitative elements (exact replicate n for each specific junction comparison, raw spreadsheet values for junction ratios, and statistical effect sizes beyond p-value thresholds) are not fully extractable from the provided excerpt, limiting full re-analysis here.


    Feedback:    

    Updated: April 15, 2026

     BGPT Paper Review


    Study Novelty

    90%

    The novelty is high because the paper claims a direct enzymatic mechanism (HDAC11-mediated de-myristoylation of a core splice factor SF3B2 at K10) that causally links an HDAC family member to a specific alternative-splicing outcome (AR-v7) in a cancer-type-dependent manner, rather than indirect cotranscriptional correlations.


    Scientific Quality

    80%

    Scientific quality is supported by the mechanistic ladder (MS substrate discovery β†’ catalytic-dead dependence β†’ PTM site mapping β†’ RIP binding β†’ splicing readouts with rescue/mimic). Main quality risks (as surfaced in the paper text) include Alk14-dependent assay perturbations and limited endogenous PTM detectability, plus cell-type specificity not fully resolved.


    Study Generality

    70%

    Generality is moderate because the strongest functional evidence is for AR-v7 splicing in selected HCC/prostate cancer cell lines; the authors acknowledge that other splice targets are untested in the provided study scope and that genome-wide splicing changes require further deep RNA-seq.


    Study Usefulness

    80%

    Useful for mechanism-focused researchers studying lysine acylation/deacylation and splice factor regulation, because it provides an experimentally testable PTM locus (SF3B2 K10) and an HDAC–splicing causal framework.


    Study Reproducibility

    70%

    Moderately high because the excerpt provides substantial procedural methods detail (constructs, cell handling, Alk14 workflow, RIP and qPCR logic). However, the excerpt lacks full raw numeric data tables needed for complete independent re-derivation of every figure’s effect size.


    Explanatory Depth

    80%

    Depth is high for a paper at this stage: it proposes a specific enzymatic PTM mechanism and ties it to RNA binding and splicing output with catalytic dependence and mutant mimic/rescue logic. Depth is limited by unresolved interplay with SUMOylation (presented as suggestive) and lack of genome-wide splice landscapes.


    🎁 Authors: Collect 451 Free Science Tokens (β‰ˆ $45.1 USD)

    Claim My Author Tokens

    Use for 112 days of free BGPT access (4 tokens = 1 day) or trade/sell (β‰ˆ $45.1 USD)

     Top Data Sources ExportMCP


     Analysis Wizard



    It will parse the provided excerpt text to extract every assay name and its claimed directional effect (HDAC11→PTM→RIP→AR-v7 splicing), then render a structured evidence matrix for falsification audit.



     Hypothesis Graveyard


    A strong null would be that the observed AR-v7 splicing changes are an indirect stress response from Alk14 labeling or from overexpression/KD artifacts rather than PTM state; this is less supported because the study includes catalytic-dead HDAC11 logic and K10R mimic/rescue architecture.


    Another discarded alternative is that SF3B2 K10R only changes splicing by altering protein stability/localization rather than RNA binding; this is undermined (in the text) by the reported lack of major SF3B2 localization/stability changes from HDAC11 KD.

     Science Art


    Paper Review: HDAC11 Regulates RNA Splicing via De-Fatty Acylation of SF3B2 Science Art

     Science Movie


    Make a narrated HD Science movie for this answer ($32 per minute)




     Discussion








    Get Ahead With Science Insights

    Custom summaries of the latest cutting edge Science research. Every Friday. No Ads.


    My BGPT






     Trending